Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for MM

HealthTree Podcast for Multiple Myeloma


Follow This Show

Stay in the know about new episodes and updates.
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The immune system may be a key factor. David Chung, MD, PhD of Memorial Sloan Kettering Cancer Center was... more

In the World Series and the world of baseball, a strategy for success means planning ahead - doing everything you can to come out a winner. In the world of multiple myeloma, that means being your best advocate and coming up with... more

African Americans are twice as likely to be diagnosed with the rare blood cancer called multiple myeloma than white Americans and other ethnicities. Why is this and what can we do to ensure that this population obtains their very best care?... more

Stand Up To Cancer has announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of... more

At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators... more

The myeloma landscape is rapidly changing with many new advancements. Paul Richardson, MD of the Dana Farber Cancer Institute joins Myeloma Crowd Radio to share recent updates from major summer meetings including the... more

How do multiple myeloma patients get into clinical trials? Especially those using popular new science like CAR T therapy? Brian McMahon, founder of SparkCures shares tips and tricks to get into these trials. Brian is the founder of SparkCures,... more

Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to... more

A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale. HealthTree will help myeloma patients... more

Adequate treatment of multiple myeloma at diagnosis is a key issue for patients because their first remission is typically the longest and most durable. Dr. Luciano Costa of the University of Alabama joins Myeloma Crowd Radio to discuss a trial... more
Show Extras

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled